Home | About CytoJournalEditorial Board | Archived articles | Search CytoJ Articles | Subscribe | Peer review policies | CytoJournal Quiz Cases
  Reviewer corner | Author corner | OA Steward’s corner | CF member’s corner | Join as CF member | Manuscript submission | Open Access (OA) Advocacy
Home
CytoJournal All 'FULL TEXT' in HTML are FREE under "open access" charter of CytoJournal.
To login for downloading any PDF OR to request TOC (Table of Content) by e-mail, please click here
Home Email this page Print this page Small font size Default font size Increase font size Cytopathology Foundation
Navigate here
  Search
 
  
Resource links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (355 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)  

 
  In this article
 »  References

 Article Access Statistics
    Viewed2847    
    Printed77    
    Emailed0    
    PDF Downloaded15    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 


 
Browse articles
LETTER TO EDITOR
CytoJournal 2012,  9:3

Authors' Reply


1 Department of Pathology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15261, USA
2 Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA

Date of Submission13-Dec-2011
Date of Acceptance14-Dec-2011
Date of Web Publication31-Jan-2012

Correspondence Address:
Zubair Baloch
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1742-6413.92416

Rights and Permissions



How to cite this article:
Griffin AC, Schwartz LE, Baloch Z. Authors' Reply. CytoJournal 2012;9:3

How to cite this URL:
Griffin AC, Schwartz LE, Baloch Z. Authors' Reply. CytoJournal [serial online] 2012 [cited 2017 Apr 23];9:3. Available from: http://www.cytojournal.com/text.asp?2012/9/1/3/92416


Sir,

We greatly appreciate the comments [1] on our recent article, 'Utility of on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspiration specimens (EBUS-TBNA)'. [2] The perspective put forth by the authors of the letter is extremely valuable, as it illustrates the variation in the practice of EBUS-TNBA, with and without rapid on-site evaluation (ROSE) across institutions.

While we acknowledge that performing EBUS-TBNAs in an Operating Room under general anesthesia allows for immediate transition to mediastinoscopy, this is not the common practice at our institution, for several reasons. By performing EBUS-TBNA procedures under conscious sedation our patients are able to avoid the expense as well as the morbidity associated with the use of an Operating Room and general anesthesia. The success of our experienced EBUS operators, as shown by our overall diagnostic rate of greater than 90%, further supports our institutional practice, as few patients subsequently undergo the more invasive mediastinoscopy.

We have reviewed the Gibson, et al. article cited by the authors. [3] Although we acknowledge that the article by Gibson, et al., addresses the use of ROSE as a means to triage a patient for mediastinoscopy, it fails to critically analyze the role ROSE plays in triaging the specimens for ancillary studies, as compared to those performed without ROSE. Furthermore, while the authors of the letter suggest that ROSE has greatly assisted them in triaging their specimens, they do not offer evidence to support this statement.

We believe that our data delivers an important message; that the work-up of a patient's specimen is not compromised by a clinician's decision not to pursue ROSE. As shown in our study, a cell block was produced and a diagnosis achieved in nearly all specimens obtained with and without ROSE at similar rates (92 vs. 88% and 94 vs. 90%, respectively). As explained in our article the specimens from patients who did not undergo ROSE were routinely processed as liquid-prep and cell-block preparations, thus avoiding 'unnecessary slides,' and conserving material for ancillary testing. Furthermore, the finding that more of our malignant specimens with ROSE had immunostains performed (63 vs. 37%), likely reflects the differences in the patient's clinical presentation, the underlying diagnosis, and the need for immunostaining, to render a definitive diagnosis rather than the material available. We would also recommend against drawing conclusions from our data on flow cytometry, given its use in only 17 of 294 (6%) specimens.

We do acknowledge that our article did not address the use of EBUSspecimens for molecular testing. However, a recent article from our institution evaluated our experience with using cytology specimens for molecular testing and showed these to be a suitable alternative to surgical biopsies. [4]

The authors' letter stresses the importance of each institution's experience in the formulation of an EBUS-TBNA protocol, with respect to ROSE. We firmly agree, and feel that our study has assisted us by refining our practice and providing better patient care.

 
 » References Top

1.Monaco SE, Pantanowitz L, Khalbuss WE. Comparing endobronchial ultrasound-guided fine needle aspiration specimens with and without rapid on-site evaluation. Cytojournal 2011;8. [In Press].  Back to cited text no. 1
    
2.Griffin AC, Schwartz LE, Baloch ZW. Utility of on-site evaluation of endobronchialultrasound-guided transbronchial needle aspiration specimens. Cytojournal 2011:8:20.  Back to cited text no. 2
    
3.Gilbert S, Wilson DO, Christie NA, Luketich JD, Landreneau RJ, Close JM,et al. Should endobronchial ultrasonography be part of the thoracic surgeon's armamentarium? J Thorac Cardiovasc Surg 2009;137:413-8.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Aisner DL, Deshpande C, Baloch Z, Watt CD, Litzky LA, Malhotra B, et al. Evaluation of EGFR mutation status in cytology specimens: An institutional experience. Diagn Cytopathol 2011. [In Press].  Back to cited text no. 4
    



This article has been cited by
1 result 1 Document Announcement of first time Cytojournal impact factor for 2012 coincides with Cytojournal decade celebration (2004-2013)
Shidham, V.B., Demay, R.M.
CytoJournal. 2013;
[Pubmed]



 

Top
Previous article Next article

    

  Site Map | Copyright and Disclaimer
© 2007 - CytoJournal | A journal by Cytopathology Foundation Inc with Wolters Kluwer - Medknow
New version online since 1st July '08
Open Access